LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS/MS methodCLINICA CHIMICA ACTAIF2.92024-07-012OAAI
Transcript, protein, metabolite and cellular studies in skin fibroblasts demonstrate variable pathogenic impacts of NPC1 mutationsORPHANET JOURNAL OF RARE DISEASESIF3.52020-04-059OAAI
Specific storage of glycoconjugates with terminal α-galactosyl moieties in the exocrine pancreas of Fabry disease patients with blood group BGLYCOBIOLOGYIF3.32018-03-146OAAI
Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imagingANALYTICAL AND BIOANALYTICAL CHEMISTRYIF3.82014-12-2719PREAI
Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophyCLINICA CHIMICA ACTAIF2.92013-10-0117OAAI
Replacement of α-galactosidase A in Fabry disease:: effect on fibroblast cultures compared with biopsied tissues of treated patientsVIRCHOWS ARCHIVIF3.12008-03-2035OAAI
Mucolipidosis IV: Report of a case with ocular restricted phenotype caused by leaky splice mutationAMERICAN JOURNAL OF OPHTHALMOLOGYIF4.22007-04-0118PREAI
Lactosylceramide in lysosomal storage disorders.: A comparative immunohistochemical and biochemical studyVIRCHOWS ARCHIVIF3.12005-05-2613PRE
Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseasesJOURNAL OF LIPID RESEARCHIF4.12002-07-0130OAAI
A NEW WAY TO CARCINOGENICITY OF AZO DYES - THE BENZENEDIAZONIUM ION FORMED FROM A NON-AMINOAZO DYE, 1-PHENYLAZO-2-HYDROXYNAPHTHALENE(SUDAN-I) BY MICROSOMAL-ENZYMES BINDS TO DEOXYGUANOSINE RESIDUES OF DNACANCER LETTERSIF10.11988-06-0148PRE
THE 1ST IDENTIFICATION OF THE BENZENEDIAZONIUM ION FORMATION FROM A NON-AMINOAZO DYE, 1-PHENYLAZO-2-HYDROXYNAPHTHALENE (SUDAN-I) BY MICROSOMES OF RAT LIVERSCANCER LETTERSIF10.11988-06-0159PRE